Related Experiment Video
Updated: Jan 11, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
Published on: October 9, 2014
The CoREST Complex Regulates Alternative Splicing by the Transcriptional Regulation of RNA Processing Genes in
Abdul Aziz Khan1, Ariel A Aptekmann1, Dongkook Min1
1Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.
Abstract:
RNA maturation, particularly splicing, depends on coordinated actions of RNA-binding proteins through post-transcriptional processing and constitutes a central mechanism of gene regulation. Aberrant splicing is associated with various diseases, including cancer. Here, we show that the CoREST complex, in coordination with c-MYC, transcriptionally regulates a subset of RNA processing genes, including those encoding essential small nuclear ribonucleoproteins (snRNPs) required for proper spliceosome function. Genetic depletion or the pharmacological inhibition of the CoREST complex in melanoma cells disrupted spliceosome activity, leading to widespread changes in alternative mRNA isoform expression and reduced cell viability. These splicing alterations were associated with changes in the 2'-O-methylation (Nm) of U1 snRNA, a modification critical for spliceosomal function. The ectopic expression of the nucleolar protein NOLC1, a downstream target of the CoREST complex and known for its role in ribosomal RNA processing, partially rescued viability, splicing patterns, and U1 snRNA methylation in CoREST-deficient melanoma cells. Conversely, NOLC1 depletion sensitized melanoma cells to the MEK inhibitor trametinib, a clinical drug approved for treating advanced melanoma. Together, these findings uncover a novel CoREST-NOLC1 axis which is a transcriptional regulatory mechanism playing a significant role in RNA splicing, highlighting that NOLC1 is a downstream effector of the CoREST complex and a potential therapeutic target for melanoma treatment.
Insights
The CoREST complex regulates RNA splicing and cell viability in melanoma by controlling RNA processing genes. Targeting the NOLC1 protein, a downstream effector, offers a potential therapeutic strategy for melanoma.
Area of Science:
- Molecular Biology
- Gene Regulation
- Cancer Research
Background:
- RNA splicing is crucial for gene regulation and its aberrations are linked to cancer.
- The CoREST complex and c-MYC coordinate transcriptional regulation of RNA processing genes.
Purpose of the Study:
- To investigate the role of the CoREST complex in regulating RNA splicing and melanoma cell viability.
- To identify downstream effectors and potential therapeutic targets within this pathway.
Main Methods:
- Genetic depletion and pharmacological inhibition of the CoREST complex in melanoma cells.
- Analysis of spliceosome activity, alternative mRNA isoform expression, and U1 snRNA methylation.
- Investigating the role of NOLC1 in rescuing CoREST-deficient phenotypes and its interaction with trametinib.
Main Results:
- CoREST complex disruption impaired spliceosome activity, altered mRNA expression, and reduced cell viability.
- Splicing changes correlated with altered U1 snRNA 2'-O-methylation.
- NOLC1 expression partially rescued CoREST-deficient phenotypes; NOLC1 depletion sensitized cells to trametinib.
Conclusions:
- A novel CoREST-NOLC1 axis transcriptionally regulates RNA splicing.
- NOLC1 is a downstream effector of CoREST and a potential therapeutic target in melanoma.
- This pathway impacts melanoma cell viability and response to MEK inhibitors.
Related Concept Videos
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
RNA Splicing
Pre-mRNA Processing: RNA Splicing
Chromatin Structure and RNA Splicing

